Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2015 Jun;21(6):1041-4.
doi: 10.3201/eid2106.140717.

Prospective multicenter international surveillance of azole resistance in Aspergillus fumigatus

J W M van der Linden, M C Arendrup, A Warris, K Lagrou, H Pelloux, P M Hauser, E Chryssanthou, E Mellado, S E Kidd, A M Tortorano, E Dannaoui, P Gaustad, J W Baddley, A Uekötter, C Lass-Flörl, N Klimko, C B Moore, D W Denning, A C Pasqualotto, C Kibbler, S Arikan-Akdagli, D Andes, J Meletiadis, L Naumiuk, M Nucci, W J G Melchers, P E Verweij
Multicenter Study

Prospective multicenter international surveillance of azole resistance in Aspergillus fumigatus

J W M van der Linden et al. Emerg Infect Dis. 2015 Jun.

Abstract

To investigate azole resistance in clinical Aspergillus isolates, we conducted prospective multicenter international surveillance. A total of 3,788 Aspergillus isolates were screened in 22 centers from 19 countries. Azole-resistant A. fumigatus was more frequently found (3.2% prevalence) than previously acknowledged, causing resistant invasive and noninvasive aspergillosis and severely compromising clinical use of azoles.

Keywords: Aspergillus; antimicrobial resistance; aspergillosis; azole resistance; fungi; international; prevalence; surveillance.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Study characteristics (number of isolates/patients screened) from 22 centers in 19 countries participating in a study of azole resistance in Aspergillus fumigatus. *Period screened was 8 months instead of 1 year in this center for unknown reason. †Total number of screened patients is unknown because this center is a reference laboratory that does not have access to patient characteristics.
Figure 2
Figure 2
Patient characteristics and underlying resistance mechanisms of patients with invasive and noninvasive Aspergillus disease. *Otomycosis, dermatomycosis, or onychomycosis; 1 patient had a resistant isolate and otomycosis (patient 9 in the online Technical Appendix Table, http://wwwnc.cdc.gov/EID/article/21/6/14-0717-Techapp1.pdf). †One patient had chronic pulmonary aspergillosis and ABPA. ‡Not classified according to European Organization for the Research and Treatment of Cancer/Mycoses Study Group criteria (5). §One patient is included with 46-bp tandem-repeat resistance mechanism. ABPA, allergic bronchopulmonary aspergillosis; CPA, chronic pulmonary aspergillosis; R, resistant; S, susceptible; –, negative; +, positive.
See this image and copyright information in PMC

Comment in

References

    1. Snelders E, van der Lee HAL, Kuijpers J, Rijs AJ, Varga J, Samson RA, et al. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med. 2008;5:e219. 10.1371/journal.pmed.0050219 - DOI - PMC - PubMed
    1. van der Linden JW, Warris A, Verweij PE. Aspergillus species intrinsically resistant to antifungal agents. Med Mycol. 2011;49:S82–9. 10.3109/13693786.2010.499916 - DOI - PubMed
    1. van der Linden JW, Snelders E, Kampinga GA, Rijnders BJ, Mattsson E, Debets-Ossenkopp YJ, et al. Clinical implications of azole resistance in Aspergillus fumigatus, the Netherlands, 2007–2009. Emerg Infect Dis. 2011;17:1846–54. 10.3201/eid1710.110226 - DOI - PMC - PubMed
    1. van der Linden JWM, Arendrup MC, van der Lee HAL, Melchers WJG, Verweij PE. Azole containing agar plates as a screening tool for azole resistance of Aspergillus fumigatus. Mycoses. 2009;52: S1–19.9.
    1. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the EORTC/MSG. Clin Infect Dis. 2008;46:1813–21. 10.1086/588660 - DOI - PMC - PubMed

Publication types